- Home
- SYRS vs GTBP Comparison
SYRS vs GTBP Comparison
Compare SYRS & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRS
- GTBP
- Stock Information
- Founded
- SYRS 2011
- GTBP 1965
- Country
- SYRS United States
- GTBP United States
- Employees
- SYRS N/A
- GTBP N/A
- Industry
- SYRS Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- SYRS Health Care
- GTBP Health Care
- Exchange
- SYRS Nasdaq
- GTBP Nasdaq
- Market Cap
- SYRS 7.1M
- GTBP 6.8M
- IPO Year
- SYRS 2016
- GTBP N/A
- Fundamental
- Price
- SYRS $0.20
- GTBP $2.40
- Analyst Decision
- SYRS Hold
- GTBP Strong Buy
- Analyst Count
- SYRS 5
- GTBP 1
- Target Price
- SYRS $3.00
- GTBP $11.00
- AVG Volume (30 Days)
- SYRS 3.2M
- GTBP 1.3M
- Earning Date
- SYRS 10-31-2024
- GTBP 11-14-2024
- Dividend Yield
- SYRS N/A
- GTBP N/A
- EPS Growth
- SYRS N/A
- GTBP N/A
- EPS
- SYRS N/A
- GTBP N/A
- Revenue
- SYRS $386,000.00
- GTBP N/A
- Revenue This Year
- SYRS N/A
- GTBP N/A
- Revenue Next Year
- SYRS N/A
- GTBP N/A
- P/E Ratio
- SYRS N/A
- GTBP N/A
- Revenue Growth
- SYRS N/A
- GTBP N/A
- 52 Week Low
- SYRS $0.18
- GTBP $1.72
- 52 Week High
- SYRS $7.96
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- SYRS 35.88
- GTBP 44.79
- Support Level
- SYRS $0.20
- GTBP $2.20
- Resistance Level
- SYRS $0.25
- GTBP $2.51
- Average True Range (ATR)
- SYRS 0.03
- GTBP 0.23
- MACD
- SYRS 0.02
- GTBP -0.04
- Stochastic Oscillator
- SYRS 5.19
- GTBP 39.16
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.